KainosMed "Expecting Resolution of Capital Erosion Concerns"

[Asia Economy Reporter Hyungsoo Park] Kainosmed, a developer of central nervous system disease treatments, expects its financial structure to improve upon completing a rights offering.

A Kainosmed representative explained, "Once the ongoing rights offering is completed, all financial structure issues such as capital erosion will be resolved for the coming years," adding, "Based on a stable financial structure, we will be able to fully focus on research, clinical development, and business development."

Kainosmed is developing KM-819 as a treatment for neurodegenerative diseases. It is conducting Phase 2 clinical trials for two indications?Parkinson's disease and multiple system atrophy (MSA)?in the United States and Korea, respectively. In Korea, dosing for the MSA clinical trial is scheduled to begin between October and November this year. They also stated that the Phase 2 clinical trial for the Parkinson's disease treatment KM-819 is underway in the United States.

Kainosmed's AIDS treatment KM-023 is currently under sales and product approval review in China as ACC007 and ACC008. ACC007, prescribed alongside existing antiretroviral drugs tenofovir (TDF) and lamivudine (3TC), began sales this year. It has been listed under health insurance, and sales are expected to continuously increase in the Chinese AIDS treatment market, which exceeds 1 trillion KRW.

ACC008 is a single-combination tablet containing tenofovir (TDF) and lamivudine (3TC), requiring only one pill per day. This eliminates the need for other antiretroviral drugs, reducing patients' medication burden and improving adherence. The Phase 3 clinical trial for ACC008 completed enrollment of 762 participants last April. Approval is expected in the second half of this year. Once ACC008 also receives product approval, Kainosmed's sales could increase through market expansion with ACC007 and ACC008.

The company also introduced its future major business plans. It expects growth in royalties from AIDS treatment sales in China and is considering sales in other countries such as India. Upon securing early efficacy data through clinical trials for Parkinson's and MSA treatments, it plans to pursue technology transfer. Stable sales growth is anticipated in the healthcare new business sector, and concrete results are expected in the exosome-based anticancer treatment research field.

This content was produced with the assistance of AI translation services.